Looking forward to a 10 cent share price, page-41

supercendol,

I think you worry too much when the sp is low.

"What if Leslie & Paul knew since last year that Her-Vaxx didn't perform as good as intended. That's why they raised the CR at end of 2017 to ensure Ph2 $$ so they can continue the show.

Then mid 2018 they raised another CR as they know Her-Vaxx is definitely not good enough for big pharma to pounce. This was done to ensure further line of products. So the Mayo/OSU CR was a desperation job to safe IMU as they knew Her-Vaxx failed."

For a start, patients taking cancer immunotherpies are known to get worse before getting better. So end of 2017 is far too early to know if our vaccine works.

But, if we go for your worse scenario idea and imu panicked because our B cell therapy wasn't working, why would they then buy a whole load more B cell therapies?

We have 9 out of 10 responders, 5 of which have seen quite a dramatic tumour reduction in a small space of time. The 1 none responder might still respond, as in theory the patients keep producing their own antibodies now.

But just as important, no safety issues at all!

Cheers